Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Clinical Trial

This study aimed to examine the effects of hesperidin supplement on the glycemic parameters, oxidative DNA damage, and lipid peroxidation in patients with type 2 diabetes. Sixty-four patients were randomly allocated to receive 500 mg/day hesperidin or placebo capsules for 6 weeks. Data on glycemic parameters, total antioxidant capacity (TAC), 8-hydroxydeoxyguanosine (8-OHDG), and malondialdehyde (MDA) were collected at the baseline and at the end of the study. In hesperidin group, TAC increased (0.74 +/- 0.16 vs. 0.82 +/- 0.18), while serum froctoseamin (5.79 +/- 5.86 vs. 5.01 +/- 4.95; p = 0.001), 8-OHDG (14.32 +/- 6.4 vs. 11.00 +/- 7.0; p = 0.000), and MDA (5.78 +/- 1.76 vs. 4.60 +/- 0.75; p = 0.000) decreased in comparison with the baseline values. There was a significant difference in percent change of TAC (13.35 +/- 19.21 vs. 3.13 +/- 10.02; p = 0.043), froctoseamin (-10.10 +/- 16.84 vs. 4.27 +/- 34.646), 8-OHDG (-25.11 +/- 28.23 vs. 8.69 +/- 35.41; p = 0.000), and MDA (-16.46 +/- 18.04 vs. -1.82 +/- 22.63; p = 0.007) between hesperidin and control groups following intervention in adjusted models. These results suggest that hesperidin may improve TAC and alleviate serum froctoseamin, 8-OHDG, and MDA levels in type 2 diabetes. Copyright (C) 2017 John Wiley & Sons, Ltd.